Emerging FcRn Inhibitors Set to Disrupt Treatment Paradigms in 20+...

agregó una foto Health

2025-07-09 12:20:05

Emerging FcRn Inhibitors Set to Disrupt Treatment Paradigms in 20+ Indications

The autoimmune treatment paradigm has undergone a fundamental transformation with the introduction of Argenx's VYVGART, the groundbreaking first-approved FcRn inhibitor that has redefined therapeutic possibilities. This innovative medicine has demonstrated exceptional clinical outcomes in generalized myasthenia gravis (gMG) treatment while simultaneously advancing through clinical development...

0 Commentarios 0 Acciones 88 Views 0 Vista previa